Background and Purpose-Patients with atrial fibrillation have a varied risk of stroke, depending on age and comorbid conditions. The objective of this study was to assess the predictive value of stroke risk classification schemes and to identify patients with atrial fibrillation who are at substantial risk of stroke despite optimal anticoagulant therapy. van Walraven, and CHADS 2 -were compared for their ability to predict ischemic stroke in patients receiving anticoagulant therapy. Data came from the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation III and V trials, which compared the efficacy of adjusted-dose warfarin and the direct thrombin inhibitor ximelagatran (36 mg twice daily) in preventing thromboembolic events in 7329 patients with chronic or paroxysmal nonvalvular atrial fibrillation who were at moderate or high risk of ischemic stroke. The main outcome measure was ischemic stroke, as determined by a central event adjudication committee. Results-During 11 245 patient-years of follow-up, 159 patients had an ischemic stroke (1.4%/year). As indicated by c statistics and hazard ratios, 3 of the classification schemes predicted stroke significantly better than chance: Framingham (cϭ0.64), CHADS 2 (cϭ0.65), and SPAF (cϭ0.61). Conclusions-In a large cohort of atrial fibrillation patients at moderate or high risk of ischemic stroke treated with warfarin or ximelagatran, the CHADS 2 , SPAF, and Framingham schemes had greater predictive accuracy than chance. This predictive ability may allow clinicians to target high-risk patients for more aggressive intervention.
A trial fibrillation (AF), the most common cardiac arrhythmia, affects Ͼ2 million individuals in the United States. 1 Much of AF-related morbidity resides in the 5-to 6-fold increased risk of ischemic stroke. 2 Although anticoagulant and antiplatelet therapies reduce the incidence of stroke in AF patients, 3 the risks of both stroke and bleeding vary. 4 Accordingly, several schemes exist to risk-stratify the nonvalvular AF population to help select appropriate candidates for anticoagulant therapy. [5] [6] [7] [8] [9] [10] [11] Existing risk stratification schemes use age and comorbid conditions, such as prior ischemic stroke, diabetes, heart failure, and hypertension, to classify patients as being at low, moderate, or high thromboembolic risk. Risk classification guides therapy with aspirin or warfarin. 1, 6, 9 The American College of Chest Physicians (ACCP) at its Consensus Conference on Antithrombotic Therapy has promulgated the most recognized schemes. 6, 9 Other accepted schemes include the AF Investigators (AFI), 5 Stroke Prevention in Atrial Fibrillation (SPAF), 8 Framingham, 11 CHADS 2 , 7, 12 and van Walraven. 10 The stratification schemes vary in estimated stroke risk assigned to individual patients and perhaps in predictive ability.
The risk-stratification schemes arose from studies of patients not receiving anticoagulant therapy. Their predictive abilities in patients receiving anticoagulant therapy are unknown. In the Stroke Prevention using an ORal Thrombin Inhibitor in atrial Fibrillation (SPORTIF) III and SPORTIF V trials, all patients received anticoagulation. The trials compared the efficacy of warfarin with that of the oral direct thrombin inhibitor ximelagatran in preventing thromboembolic events in patients with nonvalvular AF at moderate or high risk of stroke. [13] [14] [15] This substudy of the SPORTIF trials has compared the abilities of 7 recognized classification schemes-ACCP, 6,9 AFI, 5 SPAF, 8 Framingham, 11 CHADS 2 , 7,12 and van Walraven 10 -to risk-stratify patients and predict ischemic stroke in the anticoagulated SPORTIF participants. We hypothesized that the different classification schemes would vary in their predictive ability and their stratification of stroke risk.
Subjects and Methods

Study Population
The rationale, design, and results of SPORTIF III and SPORTIF V have already been published. [13] [14] [15] These randomized, multicenter, parallel-group trials compared fixed-dose oral ximelagatran with adjusted-dose warfarin for prevention of stroke and systemic embolism in nonvalvular chronic or paroxysmal AF patients at high risk of stroke based on the ACCP 2001 AF guideline recommendations. 6 Every participant provided written, informed consent according to a protocol approved by local ethics committees and in accordance with the Declaration of Helsinki. Participants randomly received either fixed-dose ximelagatran, 36 mg twice daily, or dose-adjusted warfarin to maintain the international normalized ratio between 2.0 and 3.0. A masked, interactive, voice-response system allocated treatment according to an adaptive algorithm balanced by country, concomitant aspirin treatment at entry, and history of stroke or transient ischemic attack. Anticoagulants were administered openlabel in SPORTIF III 15 and double-blinded in SPORTIF V. 13 
Ascertainment of Outcomes
Periodic administration of a standard stroke-symptom questionnaire enhanced event detection; positive responses prompted additional evaluation. Local study-affiliated neurologists or stroke specialists, masked to treatment, assessed all possible primary events based on clinical findings and results of computed tomography or magnetic resonance imaging of the brain. A single, independent, masked central event adjudication committee reviewed the reports.
Classification Schemes
The SPAF, 8 ACCP (2001 ACCP ( , 2004 , 6, 9 van Walraven, 10 and AFI 5 schemes estimate risk based on the presence of the following various factors, alone or in combination: age, female sex, diabetes, previous stroke or transient ischemic attack, hypertension or elevated systolic blood pressure, coronary artery disease, and left ventricular dysfunction. The Framingham scheme assigns point values to each of the following risk factors: age, gender, systolic blood pressure, diabetes, and prior stroke or transient ischemic attack. 11 CHADS 2 assigns 1 point each for congestive heart failure, hypertension, age Ն75 years, and diabetes mellitus, with 2 points for a history of stroke or transient ischemic attack. 7 The greater the number of CHADS 2 or Framingham points, the greater the stroke risk.
Statistical Analyses
With the combined SPORTIF III and SPORTIF V data sets, the primary analysis for this substudy compared the predictive accuracy of the 7 classification schemes for the first occurrence of ischemic stroke. Secondary analyses assessed the predictive accuracy of the schemes for all strokes (ischemic and hemorrhagic) and separately for the composite of ischemic stroke and systemic embolic events. The intention-to-treat analyses included all randomized participants, even with incomplete follow-up and exposure truncated at the time of study withdrawal. For CHADS 2 and Framingham schemes, a Cox proportional-hazards model (SAS version 8.2; SAS Institute Inc, Cary, NC) calculated stroke rates and quantified the hazard rate for stroke for each 1-point increase in score.
Time-to-event analyses determined the predictive validity of each of the classification schemes. The c statistic, a measure of the area under the receiver operating characteristic curve, quantified the predictive validity of the classification schemes and tested the hypothesis that these classification schemes performed significantly better than chance (indicated by a c statistic of 0.5). 16, 17 The c statistic quantifies discriminant ability, whereas the hazard ratio quantifies the increased relative risk of stroke across risk strata. The 95% CIs were calculated according to the Poisson approximation. 18 To compare the CHADS 2 classification scheme, which is based on point scores (0 to 6), with the schemes that categorize patients as being at low, medium or high risk, we also analyzed the predictive value of the CHADS 2 scoring system after collapsing CHADS 2 into 3 strata: low risk (CHADS 2 0), moderate risk (CHADS 2 1 to 2), and high risk (CHADS 2 3 to 6). Likewise, collapsing Framingham scores of 0 to 7 as low-risk, 8 to 13 as moderate-risk, and 14 to 31 as high-risk strata permitted comparison of Framingham scores to other scoring systems.
Results
The baseline characteristics of the 7329 participants have been previously reported. 14 The most common risk factors were hypertension, age, coronary artery disease, and left ventricular dysfunction (Table 1 ). The percentage of participants in the low-, moderate-, and high-risk cohorts varied, based on the specific risk stratification scheme used (the Figure) . Because SPORTIF study-inclusion criteria required high-risk patients by ACCP 2001 criteria, 6 In contrast, the Framingham scheme, with the ad hoc threshold of Ն14 points, characterized the fewest participants (21.2%) as being at high risk ( Table 2 ). The Framingham and SPAF schemes classified a number of SPORTIF participants as being at low risk. CHADS 2 characterized the largest cohort of SPORTIF participants as being at intermediate risk, whereas SPAF classified almost equal numbers of participants as being at moderate and high risk.
During the 11 245 patient-years of follow-up (mean, 1.5 years/patient), 159 participants had an ischemic stroke (1.4 per 100 patient-years; Table 2 ). The highest stroke rate occurred in patients identified as being at high risk by the Framingham scheme (Tables 2 and 3 ). All schemes, other than van Walraven's, which explicitly combines moderateand high-risk patients, distinguished between moderate-and high-risk subjects. Only the Framingham and CHADS 2 schemes distinguished low-from moderate-risk SPORTIF participants (Tables 2 and 3) . No strokes occurred in the 238 patient-years categorized as low risk in CHADS 2 and the smaller low-risk cohorts defined by the van Walraven (85 patient-years) and ACCP (29 patient-years) schemes.
The SPAF, Framingham, and CHADS 2 c statistics had greater predictive accuracy for ischemic stroke than chance ( schemes were collapsed into 3 strata-low, moderate, and high-they maintained their predictive values, with c statistics of 0.61 and 0.64, respectively. CHADS 2 had numerically the highest hazard ratio per increase in risk (Table 4) . Before schema collapse, the hazard ratio was 1.48 (1.31 to 1.66) for CHADS 2 , indicating a 48% increase in ischemic stroke rate per CHADS 2 point (PϽ0.0001), and 1.10 (1.07 to 1.13) for Framingham, indicating a 10% increase per Framingham point (PϽ0.0001). This 5-fold effect ratio reflects the 5-fold greater scale for the Framingham (31-point system) compared with the CHADS 2 (6-point system; Table 3 ) scheme.
The secondary analyses for the outcome of all strokes (ischemic and hemorrhagic; nϭ74 patients) and for the outcome combining ischemic stroke and systemic embolic events (nϭ169 patients) yielded results similar to those for ischemic stroke alone. Likewise, treatment with either warPercentage of patients classified as being at low, moderate, and high risk, based on the individual risk stratification schemes. .50) schemes reflected the lack of discriminant ability of these schemes in SPORTIF participants, arising from minimal exposure for low-and moderate-risk groups, based on the SPORTIF entry criteria.
Discussion
All 7 AF stroke prediction schemes were developed and evaluated in patients not receiving anticoagulant therapy. [5] [6] [7] [8] [9] [10] [11] Clinical practice guidelines use the various risk-prediction schemes to stratify patients as being at low, moderate, or high risk; this leads to recommendations for antiplatelet or antithrombotic therapy. Although these stratification schemes help identify which patients are above a risk threshold that would lead to a benefit from anticoagulant therapy, they do not identify who remains at a higher level of risk despite the use of anticoagulant therapy. Identification of such patients might influence both clinical practice and the design of future clinical trials.
In this large cohort of AF patients at increased risk for stroke treated with warfarin or ximelagatran, the CHADS 2 , SPAF, and Framingham schemes had better accuracy and predictive value, as determined by their higher c statistics, than the AFI scheme in predicting ischemic stroke. CHADS 2 Because many clinicians will consider newer strategies in "high-risk" patients, differences in stroke prediction may affect therapy. For example, dual antithrombotic therapy with warfarin and aspirin is recommended for patients with mechanical heart valves 19 and may prevent ischemic events in selected high-risk patients with AF. 20 Likewise, high-risk patients with AF may benefit from reducing, rather than holding, warfarin therapy before elective procedures. 21 Likewise, they may more vigorously avoid subtherapeutic international normalized ratio values by using patient selfmanagement, more frequent international normalized ratio monitoring, pharmacogenetic dosing, 22 or anticoagulation clinics. Risk-prediction schemes also allow for more efficient clinical trials. Using the SPAF, Framingham, or CHADS 2 scheme, investigators could selectively recruit high-risk patients, resulting in a clinical trial with smaller sample size, greater power, or shorter duration of follow-up.
Limitations
Individuals who enroll in clinical trials may not represent the general population. In particular, SPORTIF did not have an adequate sample size for low-risk cohorts as identified by several schemes, thereby impairing the performance of all schemes to discriminate risk. Evaluating all of the prediction schemes in a population with a broader spectrum of risk could validate these findings.
Conclusions
In this large, prospective cohort of AF patients with risk factors for stroke who were randomized to warfarin or ximelagatran therapy, CHADS 2 , SPAF, and Framingham schemes had a predictive accuracy significantly greater than expected by chance. Future trials should quantify the benefit of newer strategies or novel anticoagulants in high-risk patients identified by these schemes.
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